Co-Diagnostics Inc
NASDAQ:CODX

  • LAST PRICE
    1.2900
  • TODAY'S CHANGE (%)
    0.0200 (1.5748%)
  • Bid / Lots
    1.2900/ 16
  • Ask / Lots
    1.3200/ 17
  • Open / Previous Close
    1.2600 / 1.2700
  • Day Range
    1.2501
    1.3098
  • 52 Week Range
    0.9811
    2.2299
  • Volume
    73,620

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 5, 2024

      Show headlines and story abstract

    • 9:30AM ET on Thursday Sep 05, 2024 by PR Newswire
      Companies Mentioned: CODX

      Co-Diagnostics, Inc.(Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart(R) Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. The results of the analysis show that the test should retain full reactivity against mpox strains circulating over the last year, including clade 1b.

    • 9:30AM ET on Thursday Sep 05, 2024 by Dow Jones
      Companies Mentioned: CODX

      Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

      PR Newswire

      SALT LAKE CITY, Sept. 5, 2024

      SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx(TM) Logix Smart(R) Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. The results of the analysis show that the test should retain full reactivity against mpox strains circulating over the last year, including clade 1b.

Peers Headlines